Outcomes with R-CEOP for R-CHOP-ineligible patients with diffuse large B-cell lymphoma are highly dependent on cell of origin defined by Hans criteria

Authors:

Abstract
Rituximab-based chemoimmunotherapy using R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) is the standard frontline treatment for patients with diffuse large B-cell ly...

This publication has 10 references indexed in Scilit: